Corona Remedies IPO Allotment LIVE: GMP Hints at 28% Listing Jump-Full Guide to Check Status Online
The much-awaited Corona Remedies IPO allotment is finally being released, and investor excitement is at an all-time high. With the issue drawing massive subscription numbers and the grey market premium (GMP) signaling nearly 28% listing gains, retail and institutional bidders are now keen to know whether the shares have landed in their Demat accounts.
The ₹655.37-crore IPO saw extraordinary participation, and with such high demand, allotment probability-especially for retail investors-has become extremely tight. As bidders anxiously refresh their screens, here is a detailed breakdown of how to check Corona Remedies IPO allotment status on all three platforms: BSE, NSE, and Bigshare Services (the IPO registrar).
How to Check Corona Remedies IPO Allotment Status on BSE Website
Investors wanting to check their allotment status on the BSE website can follow the simple steps below:
Steps to Check Allotment on BSE
- Visit the BSE IPO allotment page:
https://www.bseindia.com/investors/appli_check.aspx - Under “Issue Type,” select Equity.
- Choose Corona Remedies Ltd from the dropdown menu.
- Enter your Application Number or PAN.
- Complete the captcha security check.
- Click Search to view your allotment status.
How to Check Corona Remedies IPO Allotment on NSE Website
The National Stock Exchange also allows investors to view their IPO allotment status. Here’s the process:
Steps to Check Allotment on NSE
- Visit:
https://www.nseindia.com/invest/check-trades-bids-verify-ipo-bids - Select Equity & SME IPO Bid Details.
- Choose Corona Remedies (CORONA) from the dropdown.
- Enter your PAN and IPO Application Number.
- Click Submit to view your allotment.
Both platforms show real-time allotment updates. In case the website is slow due to high traffic, investors may check again later.
Corona Remedies IPO GMP Today: Signals 28% Listing Pop
As of 11 December 2025, the Corona Remedies IPO GMP stands at ₹295 per share.
With the IPO’s upper band at ₹1,062, the estimated listing price comes to:
₹1,062 + ₹295 = ₹1,357
This implies a 27.78% premium, suggesting strong demand and positive sentiment in the grey market.
The GMP is an informal indicator but often provides early insight into how the stock may perform on debut.
Brand-Building Strength Pushes Growth Momentum
Corona Remedies’ strong presence in the domestic pharmaceutical space comes from its robust portfolio of 27 “engine brands.” These high-performing brands contributed 72.34% to domestic sales in MAT June 2025.
Top brands include:
* Cor
* Trazer
* Cor9
* B-29
* Myoril
Notably, 12 brands rank among the top five in their categories-showing the company’s strong execution in brand scaling across chronic and sub-chronic therapies.
Second Fastest-Growing Pharma Company in India
Between MAT June 2022 and MAT June 2025, Corona Remedies emerged as the second fastest-growing pharmaceutical player among the top 30 companies in India.
Its domestic sales delivered a 16.77% CAGR, outperforming the broader Indian Pharmaceutical Market (IPM), which grew at 9.21%.
This highlights the company’s superior execution in marketing, distribution, and specialist-focused engagement.
Edge in Hormonal Drug Manufacturing
The company benefits from backward integration through La Chandra Pharmalab, an EU-GMP and WHO-GMP certified hormone API manufacturer in Gujarat.
Key advantages:
* Right of first refusal for hormone APIs
* Access to specialized hormone manufacturing infrastructure
* Strong position in women’s health products
This integration supports quality control and cost optimization.
Strong Revenue and Profit Growth Over the Years
Corona Remedies has shown impressive financial performance:
Revenue Growth
- FY23: ₹884 crore
- FY25: ₹1,196 crore
-> CAGR: 16.3%
Profitability
- EBITDA jumped from ₹135 crore to ₹246 crore (35% CAGR)
- PAT rose from ₹85 crore to ₹149 crore (32% CAGR)
Such consistent performance reinforces investor confidence in the IPO.
High-Quality Manufacturing Infrastructure
As of June 2025, Corona Remedies operates through two manufacturing facilities:
1️⃣ Bhayla, Gujarat
- EU-GMP & WHO-GMP certified
- Major unit for regulated markets
2️⃣ Solan, Himachal Pradesh
- WHO-GMP certified
Combined, they offer a production capacity of 1,285 million units per year across 11 lines.
The company also invests in La Chandra Labs, another EU-GMP & WHO-GMP certified facility, supporting its hormone product line.
Strategic Brand Acquisitions Drive Growth
Corona Remedies has built a strong presence by acquiring or in-licensing several high-growth brands:
- Myoril (from Sanofi-Pain Management)
- Vitneurin
- Stelbid
- Dilo DX/BM
- Obimet
- Thyrocab
Partnerships with Ferring Pharmaceuticals further deepen its presence in urology and women’s health.
Key Strengths of Corona Remedies
- Second fastest-growing company in the top 30 Indian pharma players
- Strong, diversified portfolio with scalable brands
- Nationwide sales network targeting the “middle of the pyramid” segment
- High-quality manufacturing with strict GMP compliance
- Experienced leadership supported by marquee investors
- Strong R&D and innovation capabilities
Industry Outlook: Indian Pharma Market Set for Strong Growth
India’s domestic pharma market (₹2.3 trillion in FY25) is expected to reach ₹3.3-3.5 trillion by FY30.
Growth drivers include:
* Rising chronic disease burden
* Strong healthcare penetration
* Increasing affordability
* Domestic manufacturing strength
Corona Remedies is well-positioned to capture this growth.
Key Risks to Watch
1. Heavy Dependence on Select Therapy Areas
A significant share of revenue comes from Women’s Health, Cardio-Diabetic, and Pain Management.
2. Geographic Concentration
Over 96% revenue is India-dependent.
3. Raw Material Risks
The company relies on third-party suppliers without long-term contracts.
Strong Distribution Network Across India
By June 2025, the company’s reach includes:
- 22 C&F agents
- 2,000+ distributors
- Presence across 22 states & UTs
- 2,671 medical representatives engaging specialists and super-specialists
This fuels deep market penetration.
R&D Capabilities: Innovation at the Core
Corona Remedies has two DSIR-recognized R&D units focused on:
1️⃣ New formulation development
2️⃣ Manufacturing process optimization
3️⃣ Packaging innovation
4️⃣ Process engineering
R&D is crucial for long-term product pipeline development.
IPO Details and Allotment Platforms Recap
Registrar (Bigshare Services) Allotment Steps
- Visit: bigshareonline.com
- Select Company: Corona Remedies Ltd
- Enter Application No. / Beneficiary ID / PAN
- Complete captcha
- Click Search
